Pen needles market seen reaching $4.34 billion by 2030

The pen needles market is forecast to grow from $2.99 billion in 2026 to $4.34 billion by 2030, driven by rising diabetes cases, wider use of insulin pens and growing demand for safer, more comfortable injection devices. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Pen needles are a core part of insulin delivery for diabetes care, so market growth tracks the rising need for easier, more precise self-injection. - Demand is expanding as more patients manage disease at home and as diabetes prevalence continues to climb. - The shift toward safer, thinner and shorter needles could improve comfort and treatment adherence.

What happened: - The Business Research Company projected the pen needles market will grow from $2.99 billion in 2026 to $4.34 billion by 2030. - The forecast implies a 9.7% compound annual growth rate from 2026 through 2030. - The market grew from $2.69 billion in 2025 to an estimated $2.99 billion in 2026, reflecting 11.4% growth. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Pen needles are disposable components used with insulin pens for subcutaneous injections. - The devices are designed with thin needles to reduce pain during insulin administration. - Pen needles come in different lengths and gauges to fit different patient needs. - The market’s recent growth has been supported by higher diabetes prevalence, wider adoption of insulin pens, broader access to self-injection therapies, growth in home healthcare and advances in needle manufacturing. - Future demand is expected to be lifted by greater use of GLP-1 therapies, stronger needle safety standards, higher demand for sustainable disposable medical products, more painless injection devices and a preference for home-based disease management. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The forecast points to a market shaped less by one product cycle and more by the steady expansion of diabetes care and injection-based therapies. - Growth in safer and less painful needle designs suggests competition will likely center on patient experience as much as price and supply. - The NHS reported in June 2024 that more than 549,000 additional people in England were identified as at risk of type 2 diabetes in 2023, bringing the total registered with general practitioners to 3,615,330. - That was nearly 20% higher than the 3,065,825 registered in 2022.

What's next: - Market growth is expected to continue as diabetes management shifts further toward self-care and home treatment. - Product development is likely to focus on ultra-thin needles, shorter needles and improved safety features. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables.

The bottom line: - Pen needles are set for steady expansion through 2030 as diabetes rates rise and manufacturers push for safer, more comfortable injection tools.